SciBX: Science-Business eXchange Contents: October 13 2011, Volume 4 / Issue 40

TABLE OF CONTENTS October 13 2011, Volume 4 / Issue 40 Analysis Cover Story Translational Notes Targets and Mechanisms The Distillery: Therapeutics Cancer Endocrine/metabolic disease Hematology Infectious disease Inflammation Neurology The Distillery: Techniques Assays and screens Disease models Drug platforms Imaging Markers Recommend to your library Web feed Available online only Subscribe Advertisement SciBX: Science-Business eXchange Recommend SciBX to your library today SciBx is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Subscribe to SciBX and you won't miss the next big thing. For more information visit: www.nature.com/scibx.   Trade Secrets A Nature Network blog by BIOENTREPRENEUR Brought to you by Nature Biotechnology Access the insights, advice and commentary from scientists and entrepreneurs building biotech sectors around the world. Join the global dialogue on life science entrepreneurship: http://blogs.nature.com/trade_secrets   Analysis Cover Story Top Going antiviral in brain cancer Michael J. Haas doi:10.1038/scibx.2011.1104 Swedish and Norwegian researchers have shown that targeting CMV and/or inhibiting COX-2 could help treat medulloblastoma. The findings could lead to repurposing opportunities for companies with compounds against the virus or the enzyme. Full Text | PDF Translational Notes Top TRNDing toward translation Chris Cain doi:10.1038/scibx.2011.1105 After two years of funding pilot partnerships, the NIH's Therapeutics for Rare & Neglected Diseases program has announced its first round of competitively awarded projects. The awards to three biotechs and an academic team illustrate how the NIH plans to advance a range of small molecules into the clinic. Full Text | PDF Lilly's opening moves Joanne Kotz doi:10.1038/scibx.2011.1106 Eli Lilly is rolling out its Open Innovation Drug Discovery platform to cast a wide net for finding innovative molecules from external investigators in the company's core disease focus areas. The pharma has also joined a public-private partnership being led by the Structural Genomics Consortium to identify IP-free molecules against epigenetic targets. Full Text | PDF Targets and Mechanisms Top Getting fat off PI3Kγ Tim Fulmer doi:10.1038/scibx.2011.1107 Swiss researchers have shown that knocking out PI3Kγ leads to weight loss and increased insulin sensitivity in mice. The findings strengthen the case for targeting the kinase in metabolic disorders, but designing selective compounds could pose an obstacle. Full Text | PDF Distillery: Therapeutics Cancer Top Cyclooxygenase-2 (COX-2); viral polymerase doi:10.1038/scibx.2011.1108 In vitro, primary tumor and mouse studies suggest that human cytomegalovirus (CMV) antivirals and/or COX-2 inhibitors could help treat medulloblastoma. Full Text | PDF Mammalian target of rapamycin (mTOR; FRAP; RAFT1); Ras; heat shock protein 90 (Hsp90) doi:10.1038/scibx.2011.1109 Studies in mice suggest combining Hsp90 and mTOR inhibitors could help treat Ras-driven cancers. Full Text | PDF Monocyte chemoattractant protein-1 (MCP-1; CCL2) doi:10.1038/scibx.2011.1110 In vitro and mouse studies suggest inhibiting the nitrosylation of CCL2 could help increase the efficacy of adoptive cell transfer therapy in cancer. Full Text | PDF Heat shock 70 kDa protein 5 (glucose-regulated protein, 78 kDa; HSPA5; GRP78) doi:10.1038/scibx.2011.1111 In vitro and mouse studies suggest inhibiting GRP78 could help treat leukemia. Full Text | PDF Bromodomain containing 2 (BRD2); BRD3; BRD4; c-Myc (MYC) doi:10.1038/scibx.2011.1112 A study in cell culture and in mice suggests inhibitors of BET bromodomains could help treat hematological malignancies. Full Text | PDF T cell receptor (TCR) doi:10.1038/scibx.2011.1113 In vitro and mouse studies suggest inhibiting TCR signaling could help treat T cell lymphomas. Full Text | PDF CXC chemokine receptor 2 (CXCR2; IL8RB) doi:10.1038/scibx.2011.1114 A study in mice suggests antagonizing CXCR2 could help treat pancreatic ductal adenocarcinoma. Full Text | PDF Endocrine/metabolic disease Top β-Amyloid (Aβ); microtubule-associated protein-τ (MAPT; TAU; FTDP-17) doi:10.1038/scibx.2011.1115 In vitro and cell culture studies suggest a lysine-binding small molecule can prevent or reverse amyloid formation to help treat amyloidosis. Full Text | PDF Protein kinase Bβ (PKBB; AKT2) doi:10.1038/scibx.2011.1116 Human genomic studies identified a mutation in AKT2 that could play a role in severe recurrent hypoglycemia. Full Text | PDF Phosphoinositide 3-kinase-γ (PI3Kγ) doi:10.1038/scibx.2011.1117 Mouse studies suggest that inhibiting PI3Kγ in non–bone marrow cells could help treat obesity. Full Text | PDF Hematology Top Janus kinase-2 (JAK-2) doi:10.1038/scibx.2011.1118 In vitro and mouse studies identified a 1-amino-5H-pyrido[4,3-b] indol-4-carboxamide–based JAK-2 inhibitor that could help treat myeloproliferative disorders. Full Text | PDF Infectious disease Top ATP-dependent Clp protease proteolytic subunit (clpP) doi:10.1038/scibx.2011.1119 In vitro studies identified clpP activators that could help treat bacterial infections. Full Text | PDF Not applicable doi:10.1038/scibx.2011.1120 In vitro studies suggest propafenone analogs could help treat malaria. Full Text | PDF Inflammation Top Prostaglandin D2 receptor (CRTH2; GPR44; CD294) doi:10.1038/scibx.2011.1121 In vitro and mouse studies identified phenoxyacetic acid–based antagonists of CRTH2 that could help treat allergy and inflammation. Full Text | PDF Neurology Top Corticotropin-releasing factor 1 (CRF1); microtubule-associated protein-τ (MAPT; TAU; FTDP-17) doi:10.1038/scibx.2011.1122 Mouse studies suggest antagonists of the stress response hormone CRF1 could help prevent AD. Full Text | PDF MicroRNA-34c (miR-34c) doi:10.1038/scibx.2011.1123 Mouse studies suggest increasing expression of miR-34c could help treat stress-induced anxiety. Full Text | PDF Huntingtin (HTT); ataxin 3 (ATXN3) doi:10.1038/scibx.2011.1124 In vitro and mouse studies identified peptoids that bind polyglutamate repeats and could help treat HD. Full Text | PDF Distillery: Techniques Assays and screens Top Assay to evaluate gene-drug interactions and predict chemotherapeutic resistance doi:10.1038/scibx.2011.1125 An assay to evaluate gene-drug interactions could help guide treatment choices. Full Text | PDF Disease models Top Apolipoprotein E (APOE)-mediated regulation of factors contributing to atherosclerotic lesion formation doi:10.1038/scibx.2011.1126 Mouse studies showing how APOE regulates downstream factors that contribute to atherosclerosis could help guide the development of treatments of the disease. Full Text | PDF Mouse model for autism spectrum disorder (ASD) doi:10.1038/scibx.2011.1127 A transgenic mouse model could be useful for studying the 1%–3% of ASD cases caused by duplication of the gene encoding ubiquitin protein ligase E3A (UBE3A; E6AP). Full Text | PDF Rat model for glial role in amyotrophic lateral sclerosis (ALS) doi:10.1038/scibx.2011.1128 A rat model of ALS could be useful for understanding the role of glial cells in the disease. Full Text | PDF Drug platforms Top Endothelial, colony-forming cell (ECFC) transplants for gene therapy doi:10.1038/scibx.2011.1129 In vitro and mouse studies suggest genetically engineered ECFC transplants could be used for gene therapy. Full Text | PDF Heterobivalent IgE ligands for the treatment and prevention of allergy doi:10.1038/scibx.2011.1130 In vitro studies suggest heterobivalent IgE ligands could help treat and prevent allergy. Full Text | PDF Protocol to generate oligodendrocyte progenitor cells (OPCs) from pluripotent mouse epiblast stem cells doi:10.1038/scibx.2011.1131 A protocol to differentiate mouse epiblast stem cells into OPCs could help screen for myelin-promoting drugs and test cell-based therapies. Full Text | PDF Imaging Top In vivo imaging of bone-resorbing osteoclasts to evaluate bone disease therapeutics doi:10.1038/scibx.2011.1132 In vivo imaging probes of bone-resorbing osteoclasts could help evaluate bone disease therapeutics. Full Text | PDF Markers Top CD8+ T cell gene expression profiling to determine inflammatory bowel disease (IBD) prognosis doi:10.1038/scibx.2011.1133 Patient sample studies suggest CD8+ T cell gene expression could help predict IBD progression. Full Text | PDF You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2011 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.